Your prediction
Novozymes A/S B Stock
There is an upward development for Novozymes A/S B compared to yesterday, with an increase of €1.20 (2.150%).
Our community identified positive and negative aspects for Novozymes A/S B stock for the coming years. 1 users see the criterium "Return on equity" as a plus for the Novozymes A/S B stock. On the other hand our users think that "Revenue growth" could be a problem in the future.
Pros and Cons of Novozymes A/S B in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novozymes A/S B vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novozymes A/S B | 2.150% | 4.197% | 2.883% | -1.314% | 4.273% | 26.076% | -13.824% |
| Givaudan S.A. | 0.880% | 3.795% | -4.486% | -4.280% | 4.897% | 43.387% | 43.793% |
| Ems-Chemie N | 2.690% | 4.846% | 17.795% | 27.077% | 49.831% | 55.614% | 57.270% |
| Solvay S.A. A | - | 2.036% | 2.812% | -3.288% | -0.952% | -75.276% | -75.925% |
